AVTX Stock Analysis: Buy, Sell, or Hold?
AVTX - Avalo Therapeutics, Inc. Common Stock
$19.09
0.18 (0.93%)
▲
5d:
-0.86%
30d:
+39.61%
90d:
+43.07%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When AVTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called AVTX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AVTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: AVTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AVTX is currently trading at $19.09, which is considered extended relative to its 30-day fair value range of $13.70 to $18.45.
Technical Outlook: Technically, AVTX is showing sideways momentum. Immediate support is located at $17.23, while resistance sits at $20.65.
Market Sentiment: AVTX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $44.69 (+136.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AVTX is showing sideways momentum. Immediate support is located at $17.23, while resistance sits at $20.65.
Market Sentiment: AVTX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $44.69 (+136.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$13.70 -
$18.45
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 136.3% below Wall St target ($44.69)
Trading Range Analysis
30-Day Trading Range
$13.70 -
$18.45
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$17.23
Resistance Level
$20.65
Current Trend
Sideways
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.84
Wall Street Target
$44.69
(+136.3%)
Revenue Growth (YoY)
-69.3%
Share & Embed Analysis
Last updated: July 14, 2026 12:59 PM ET
Data refreshes hourly during market hours. Next update: 1:59 PM
Data refreshes hourly during market hours. Next update: 1:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Mittie Doyle
SELL
3970 shares
2026-04-06
Christopher Ryan Sullivan
SELL
7980 shares
2026-04-02
Christopher Ryan Sullivan
SELL
7979 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
